Consumer medicine information

1. Why am I using COLISTIN LINK?

COLISTIN LINK contains the active ingredient colistimethate sodium. COLISTIN LINK is used to treat certain types of bacterial infections.
For more information, see Section 1. Why am I using COLISTIN LINK? in the full CMI.

2. What should I know before I use COLISTIN LINK?

Do not use if you have ever had an allergic reaction to COLISTIN LINK or any of the ingredients listed at the end of the CMI. COLISTIN LINK should not be used if you have myasthenia gravis.
Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.
For more information, see Section 2. What should I know before I use COLISTIN LINK? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with COLISTIN LINK and affect how it works.
A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use COLISTIN LINK?

• COLISTIN LINK is given as an injection by a doctor or other healthcare professional into a vein or muscle. You may receive doses of this medicine as injections, or infusions (via drip).

5. What should I know while using COLISTIN LINK?

6. Are there any side effects?

Side effects that require urgent medical attention include: difficulty breathing; decreased urine output or difficulty passing urine. Other possible side effects include dizziness, tingling or numbness of the mouth or tongue, itching, upset tummy, slurred speech, fever.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

1 Name of Medicine

Colistin (as colistimethate sodium).

2 Qualitative and Quantitative Composition

Colistin Link contains the sodium salt of colistimethate, a polypeptide antibiotic. Each dose contains colistimethate sodium equivalent to colistin 150 mg. When reconstituted each dose provides 150 mg of colistin in 2 mL equivalent to 4,500,000 IU antibiotic activity.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Powder for injection.
White to slightly yellow lyophilised powder cake.

4 Clinical Particulars

4.9 Overdose

Overdose can result in renal insufficiency, muscle weakness and apnoea. As in any case of overdose, colistimethate sodium therapy should be discontinued and general supportive measures should be utilised.
In albino rabbits and beagle dogs, IV doses of 5, 10 and 20 mg/kg/day for 28 days resulted in elevated blood urea nitrogen in the dog (10 mg/kg/day dose group) and in both 20 mg/kg dose groups.
For information on the management of overdose, contact the Poison Information Centre on 131 126 (Australia) or 0800 764 766 (New Zealand).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. No data available.
Carcinogenicity. No data available.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSCOLSOD.gif Molecular formula: C₅₆H₁₀₆N₁₆Na₆O₂₆S₆. Molecular weight: 1750.
CAS number. 8068-28-8.

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription Only Medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/COLISTST.gif